These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9163289)

  • 1. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
    Senderowicz AM; Vitetta E; Headlee D; Ghetie V; Uhr JW; Figg WD; Lush RM; Stetler-Stevenson M; Kershaw G; Kingma DW; Jaffe ES; Sausville EA
    Ann Intern Med; 1997 Jun; 126(11):882-5. PubMed ID: 9163289
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
    Amlot PL; Stone MJ; Cunningham D; Fay J; Newman J; Collins R; May R; McCarthy M; Richardson J; Ghetie V
    Blood; 1993 Nov; 82(9):2624-33. PubMed ID: 8219217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma.
    Ghetie MA; Podar EM; Gordon BE; Pantazis P; Uhr JW; Vitetta ES
    Int J Cancer; 1996 Sep; 68(1):93-6. PubMed ID: 8895546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
    Mansfield E; Amlot P; Pastan I; FitzGerald DJ
    Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
    Van Horssen PJ; Preijers FW; Van Oosterhout YV; Eling WM; De Witte T
    Leuk Lymphoma; 2000 Nov; 39(5-6):591-9. PubMed ID: 11342342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
    Sausville EA; Headlee D; Stetler-Stevenson M; Jaffe ES; Solomon D; Figg WD; Herdt J; Kopp WC; Rager H; Steinberg SM
    Blood; 1995 Jun; 85(12):3457-65. PubMed ID: 7780133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
    Newton DL; Hansen HJ; Liu H; Ruby D; Iordanov MS; Magun BE; Goldenberg DM; Rybak SM
    Crit Rev Oncol Hematol; 2001; 39(1-2):79-86. PubMed ID: 11418304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
    Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
    Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
    Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I
    Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two surface antigen targets for immunotoxin-mediated elimination of normal and neoplastic murine B cells.
    Parkhouse RM; Santos-Argumedo L; Teixeiral C; Henry RV; Wawrzynczak E
    Curr Top Microbiol Immunol; 1992; 182():331-5. PubMed ID: 1490372
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
    Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
    Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells.
    van Horssen PJ; van Oosterhout YV; Evers S; Backus HH; van Oijen MG; Bongaerts R; de Witte T; Preijers FW
    Leukemia; 1999 Feb; 13(2):241-9. PubMed ID: 10025898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1994 Aug; 84(3):702-7. PubMed ID: 7519071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
    Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
    Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.